Bioverativ Archives -

Oxford Biomedica’s long-running alliance with Sanofi over a pair of gene therapies for ophthalmic diseases has come to

Sanofi hands back gene therapies to Oxford Biomedica

https://pharmaphorum.com/news/sanofi-hands-back-gene-therapies-to-oxford-biomedica/

Sanofi has just spent $16 billion on acquiring Bioverativ and Ablynx – and yesterday’s Q4 results revealed why

Sanofi says biotech acquisitions will help overcome diabetes decline

https://pharmaphorum.com/news/sanofi-says-biotech-acquisitions-will-help-overcome-diabetes-decline/

French pharma makes move into haemophilia market.

After losing out on two big deals, Sanofi to buy Bioverativ for $11.6bn

https://pharmaphorum.com/news/losing-two-big-deals-sanofi-buys-bioverativ-11-6bn/

2017 could be a bumper year for M&A – but Trump’s price control threats dominate

Despite Trump price concerns, JP Morgan event anticipates M&A boom

https://pharmaphorum.com/news/jp-morgan/

Coming antibody drugs and gene therapy could transform treatment

Biogen’s haemophilia spin-out Bioverativ to launch early 2017

https://pharmaphorum.com/news/biogens-haemophilia-spin-bioverativ-launch-early-2017/

Elocta, a new drug co-marketed by Sobi and Biogen, has been approved in the European Union. The injectable

New haemophilia drug Elocta approved in Europe

https://pharmaphorum.com/news/new-haemophilia-drug-elocta-approved-in-europe/

Bioverativ